Leishmaniasis is one of the most important neglected tropical diseases (NTDs). It is caused by obligate intracellular parasites of Leishmania spp. That parasite is transmitted to humans by the bite of dipteran sandflies (Hide et al., 2007; Alvar et al., 2011; Alvar and Arana, 2018; Ryan and Ray, 2004; Torres-Guerrero et al., 2017). The parasite resides within the macrophage, where it differentiates and proliferates. There are approximately 20 species of Leishmania parasites that can infect humans, promoting three types of clinical manifestations of the disease: (i) mucocutaneous leishmaniasis (ML), cutaneous leishmaniasis (CL), and visceral leishmaniasis (VL). Each one of them is caused by a specific species of Leishmania: Leishmania infantum and Leishmania donovani promote VL, Leishmania braziliensis and Leishmania mexicana cause CL in the Americas, and Leishmania major causes CL in the Old world), and L. braziliensis and Leishmania amazonensis are responsible for MC (Hide et al., 2007; Torres-Guerrero et al., 2017). CL is described as lesions in the skin, whereas MC consists of deep lesions with deformation of the mucosa zone as a consequence of a high level of infection (Torres-Guerrero et al., 2017). Meanwhile, the VL is characterized by an over-inflammation or increase of the volume of such organs, including the bazo, the spleen (known as splenomegaly), the liver (hepatomegaly), and lymph nodes (lymphadenopathy) (Hide et al., 2007; Torres-Guerrero et al., 2017). In particular, this last clinical manifestation VL is fatal in more than 95% of untreated cases.

From a demographic point of view, leishmaniasis is prevalent in 98 countries of tropical and subtropical regions, registering between 0.7 and 1.3 million new leishmaniasis cases and between 26,000 and 65,000 deaths annually (World Health Organisation, 2024). The majority of VL cases occur in eight countries: Brazil, Eritrea, Ethiopia, India, Kenya, Somalia, South Sudan, and Sudan; the cases of CL are predominant in Afghanistan, Algeria, Brazil, Colombia, Iraq, Pakistan, and Syria; whereas the cases of MCL are found in South America (Pan American Health Organization, 2023).

Treatment of leishmaniasis represents another challenge for medicinal chemists as a consequence of the high adaptability and genetic plasticity of Leishmania. The parasite is able to elude the defense mechanism of macrophage-inducing changes in macrophage polarization as well as to quickly develop resistance to known drugs. Currently, there are neither vaccines nor effective drugs for leishmaniasis treatment in any of its clinical manifestations. There are a few approved drugs, including glucantime, pentostam, pentamidine, amphotericin B, and miltefosine (Figure 1), but they present multiple disadvantages including diverse toxicity manifestations (affecting heart, liver, and kidneys), high cost, low therapeutic efficacy, prolonged administration treatment times (30–60 days) and parasite resistance (Zulfiqar et al., 2017; Aronson et al., 2017). The use of pentavalent antimonials is currently compromised due to the many resistant cases registered in endemic areas of India and Brazil (Aronson et al., 2017). Alternatively, miltefosine has been used for the treatment of VL and CL as the first oral antileishmanial drug; however, its use is also limited by its high toxicity and effectiveness against different Leishmania species (Aronson et al., 2017).

To minimize side-effects, enhance the therapeutic effect, and reduce the emergence of parasite resistance, binary combinations between two of these approved drugs have been employed in specific regions with epidemic situations in Africa and Asia; however, the use of the combination did not provide a definitive solution. This situation has motivated the scientific community to generate new chemical structural alternatives. Many studies have been done by the academy and non-governmental organizations such as Disease Neglected Innovative (DNDi) and Asian and European consortiums. The DNDi presents a portfolio exhibiting a group of compounds that are currently under investigation in preclinical or clinical stages, with a promising therapeutic profile, including (i) proteasome inhibitors such as GNF8000, GNF6702, LXE408, and DDD01305143/GSK3494245 (preclinical stage); (ii) inhibitors of cyclin-dependent kinase-12 (CDK-12), such as DDD853651/GSK3186899 (preclinical stage); (iii) nitroimidazole compounds such as DNDi-VL2098, DNDi-VL2075, DNDi-VL8219, and DNDi-VL0690 (preclinical stage), (iv) benzoxaboroles, such as DNDi-VL6148 (clinical stage) and DNDi-5421 and DNDi-5640 (preclinical stage), and (v) amino-pyrroles such as DNDi-5561, DNDi-1047, and DNDi-1044 (preclinical stage) (Drugs for Neglected Diseases initiative, 2023). Other heterocyclic derivatives developed by Hilbert´s group are in the preclinical phase (Thomas et al., 2019; Thomas et al., 2021) (Figure 2).

Despite the advances, the development of new leishmanicidal drugs remains a significant challenge for medicinal chemists, not only because of the rigorous pharmacological requirements, which seek to minimize side-effect risks, but also because of the genetic plasticity of the parasite and the challenge of effectively accessing a parasite resident in the host cell. That situation calls for the development of new strategies to identify new effective, selective, and safe leishmanicidal agents, which will not only be focused on classic medicinal chemistry concepts but also on critical aspects of parasite survival (Alvar and Arana, 2018). In this sense, quinoline represents a prominent scaffold for the leishmanicidal drug design due not only to its structural versatility for introducing key pharmacophores but also to the plasticity of the chemical system to be targeted on diverse key aspects of parasite life (Silva et al., 2023; Reynolds et al., 2013; Dorababu, 2021). Details concerning the relationship of the quinoline with critical aspects of Leishmania life are shown in Section 2.

When considering quinolines as leishmanicidal agents, there are many examples that feature a variety of pharmacophores (Silva et al., 2023). In the first studies, antimalarial quinolines such as chloroquine, mefloquine, primaquine, sitamaquine, and tafenoquine (Figure 3) were commonly employed upon repurposing program for the discovery of potential quinoline drugs (Reynolds et al., 2013). From active antimalarial agents, sitamaquine (WR 6026, Figure 3) was identified as the most promising quinoline for the treatment of VL not only by its good antileishmanial activity but also its good aqueous solubility for oral administration, excellent pharmacokinetic (short half-time elimination) and ADME parameters (Loiseau et al., 2011; Coimbra et al., 2010). That quinoline drug has reached clinical trials (phase II) for the treatment of VL caused by Leishmania chagasi (Dietze et al., 2001); however, its investigation has been stopped due to their adverse effects including methemoglobinemia and nephrotoxicity (Dietze et al., 2001). It is important that the potential of sitamaquine as a leishmanicidal agent is restricted to the treatment of VL because poor or discrete results have been found against in vivo models of CL under different topical formulations (Garnier et al., 2006).

Among other antimalarial quinolines used against the Leishmania parasite, a group of 8-substituted quinoline such as the 8-hydroxyquinoline A, tafenoquine and primaquine (see structures in Figure 3) have been identified by their excellent leishmanicidal response against in vitro infective models (Costa Rocha et al., 2013). The 8-hydroxyquinoline A that presents a better leishmanicidal profile than the reference drug miltefosine is in the preclinical stage within the Drugs for Neglected Diseases initiative (DNDi) program (Loiseau et al., 2011). Tafenoquine exhibits a good leishmanicial in vitro profile against a variety of Leishmania species as well as a curative response for the in vivo murine model of L. donovani/BALB/c with a low ED₅₀ dose (1.2–3.5 mg/kg for 5 days) (Manzano et al., 2011). Mechanistic studies revealed that tafenoquine (i) targets respiratory complex III with apoptosis consequences and (ii) is able to increase glycolytic ATP synthesis via a sterol-dependent diffusion process. Meanwhile, good in vitro and in vivo responses for LV models with nontoxic effects were found for primaquine (Shah et al., 2022). However, the potential of the 8-amino/hydroxyquinolines seems to be limited by their tentative side effects (Costa Rocha et al., 2013), making the development of more effective and safer quinolines essential.

In this context, the 4-aminoquinoline emerges as a convenient scaffold, for which a great variety of active compounds against different in vitro and in vivo models of either VL or CL have been identified (see Section 3). Examples of 4-aminoquinolines include chloroquine, hydroxychloroquine, and an analog such as mefloquine (see structures in Figure 3). Chloroquine has shown a better response against in vitro and in vivo models of CL than models of VL (Costa Rocha et al., 2013; Hanif et al., 2016; Mwololo et al., 2015). Against intracellular amastigotes of L. amazonensis in infected macrophages, for example, the chloroquine and other analogs such as mefloquine and hydroxychloroquine exhibited significant antiamastigote response, with IC₅₀ values of 0.78 μM, 1.56 μM, and 0.67 μM, respectively. Interestingly, a more discrete response was found against promastigotes with IC₅₀ values higher than 8 µM (Costa Rocha et al., 2013). Studies at the clinical level have shown the curative properties of chloroquine in infected patients, finding better results upon intralesional administration than upon oral administration (Hanif et al., 2016). Meanwhile, amodiaquine, a traditional 4-aminoquinoline antimalarial drug, has also been demonstrated to possess a remarkable antiproliferative effect against different Leishmania species with low IC₅₀ responses (De Mello et al., 2004). As a consequence of the potential of the 4-aminoquinoline, many active and selective leishmanicidal agents based on 4-aminoquinoline have proved in the last 2 decades against in vitro and in vivo models of CL and VL, making it possible to recognize specific structural requirements and well-defined mechanistic targets for a rational drug design.

This review provides a general perspective on the key issues to consider for the design of safe and selective leishmanicidal agents based on 4-aminoquinolines. The review analyzed the evolution and development of 4-aminoquinolines as leishmanicidal agents focused on two critical aspects: (i) a recompilation of the typical molecular or cellular targets involving 4-aminoquinoline and (ii) a structure–property relationship analysis among key examples. The structure–property relationship seeks to identify the key pharmacophore from biological potency, selectivity, and physicochemical convenience, whereas the mechanistic insight seeks to identify the key targets for the design of a quinoline with a specific biological response. With that information, we seek to offer readers a tool to face the drug design of leishmanicidal agents based on 4-aminoquinolines.

This section presents the main biological targets in which the 4-aminoquinolines are involved as leishmanicidal agents. These therapeutic targets are keys to promoting a specific and selective leishmanicidal response, and they have been identified from the in vitro and in vivo experiments of CL and VL models. Among the most typical targets can be mentioned: (i) accumulation into the mitochondria of the Leishmania parasite leading to depolarization of the mitochondrial membrane potential; (ii) accumulation into the macrophage phagolysosome to favor parasite–drug interaction and (iii) immunostimulation of the host cell.

4-Aminoquinoline is the most versatile quinoline scaffold for the construction of active and potent leishmanicidal agents. In particular, the most promising 4-aminoquinolines are characterized by a tertiary amine or/and a lipophilic group (e.g., alkyl or aryl) into the amino chain. In this section, we performed a structure–activity relationship comparison to provide a general perspective about the key structural features for the design of potent leishmanicidal agents based on 4-aminoquinoline and a direct correlation with the three mentioned targets.

Within the 4-aminoquinolines, chloroquine was one of the first antimalarial quinoline compounds to test against Leishmania models, with an excellent in vitro response against intracellular amastigotes of the L. amazonensis parasite (Costa Rocha et al., 2013). In a clinical trial, chloroquine appeared to be as effective as tetracycline for the treatment of CL (Hanif et al., 2016). Its combination with diminazene provided good leishmanicidal responses that merit further development (De Mello et al., 2004), whereas its combination with paromomycin did not yield encouraging results. In summary, chloroquine displayed a good leishmanicidal response against CL models, but its leishmanicidal response is discrete or weak against VL models (Mwololo et al., 2015).

Another antimalarial 4-aminoquinoline that has been proved against Leishmania parasites is amodiaquine. Amodiaquine is a popular antimalarial once used for human treatment, but its use was suppressed by the occurrence of hepatotoxicity due to the metabolization of amodiaquine to form quinone intermediate via hydroxyl oxidation (O’Neill et al., 2003). The amodiaquine has shown an excellent in vitro response against intracellular amastigotes of L. donovani with a selectivity index (SI) higher than 90 (Guglielmo et al., 2009). Beyond the known antimalarial 4-aminoquinolines (chloroquine, amodiaquine, others), the 4-aminoquinoline scaffold has been widely used as a platform for the construction of new leishmanicidal agents.

We performed a chronological (since 2009) summary of current examples of leishmanicidal 4-aminoquinolines, and from them, a structure–property relationship analysis and the correlation of the biological activity with mitochondrial dysfunction and immunostimulation of host cells were made for those cases where mechanistic data were reported. Furthermore, the specificity of 4-aminoquinolines toward intracellular amastigotes in infected in vitro models over promastigote or axenic amastigote in vitro models was discussed for most of the cases.

In 2009, S. Gugliemo and co-workers prepared a series of 22 novel analogs of amodiaquine functionalized with an N-heteroaryl-piperazine (Guglielmo et al., 2009), a 4-(dialkyl)ethylene-diamine, or an N-acyl 4-(dialkyl)ethylene-diamine as the N-amine terminal into the 4-aniline moiety (Figure 10), and its leishmanicidal in vitro effect against L. donovani (responsible of VL) amastigotes was proved. Within the 4-aniline substituted derivatives, the replacement of the terminal N-diethylamino in the AQ by hydroxyl-methyl or chloro-methyl moieties resulted in a significant decrease of the leishmanicidal activity for their amodiaquine analogs by more than 80-fold against the intracellular amastigotes of L. donovani. This implies that the presence of the basic terminal amine, a pharmacophore, is essential for the design of new amodiaquine leishmanicidal quinolines. Derivatives featuring a 4-(dialkyl)ethylene-diamine, group II, showed an antiamastigote response depending on the type of N-substitution at the end of the diamine chain. For example, the incorporation of amine (NH₂) or leucine amino acid generates the compounds most active in the family (group II), with IC₅₀ values of 5.65 µM and 4.69 µM and selectivity indexes of 4.5 and 4.8, respectively. These results show the important role of the terminal amino group, but further improvements are needed to reach the potency found for AQ [selectivity index (SI) of about 90].

The remaining compounds with acyl-amine moieties as terminal substituents showed a similar leishmanicidal activity but higher toxicity, which compromises the selectivity of their analogs. Finally, from group III, the incorporation of heteroaromatic basic moieties was not convenient because their analogs displayed a comparable IC₅₀ lower than AQ, but their derivatives were highly toxic, with an SI lower than 3. Only a derivative with a thienyl, a not basic moiety, displayed an acceptable selectivity (SI = 5.5) derived from an IC₅₀ of 9.14 µM and a CC₅₀ of 50.4 µM, whereas other analogs with a benzothiazolyl moiety showed a selectivity index of 3.5 and an IC₅₀ of 12.9 µM and a CC₅₀ of 45.2 µM.

From the results, it is clear that the amodiaquine represents a lead platform for the leishmanicidal drug design, and the elongation of the amino chain by the incorporation of an extra group (e.g., amino, acyl-amino, or basic heteroaryl) did not improve the leishmanicidal response compared with the amodiaquine standard. No mechanism of action assays were performed.

In 2010, E.S. Coimbra and co-workers prepared a series of three N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines (compound 11, 12 and 13, Figure 11A) (Coimbra et al., 2010), and they were proved against promastigotes of L. braziliensis, L. amazonensis, L. chagasi, and L. major parasites. In general, these derivatives showed a weak or no leishmanicidal response (IC₅₀ > 200 µM) against the different promastigote Leishmania spp. In particular, the derivative with the ester moiety as an R substituent (compound 13) was the most active of the compounds, whereas the compounds with carboxylic moiety (compound 14) proved to be highly toxic and less selective with an IC₅₀ higher than 200 µM and a CC₅₀ of approximately 10 µM on Vero and kB cells. These results indicate that a minimal lipophilicity is an essential requirement for the design of a leishmanicidal 7-chloroquinoline featuring a 4-(dialkyl)ethylene-diamine chain. As was described in Section 3, most of the 4-aminoquinolines are usually more active against intracellular amastigotes than promastigotes or axenic amastigotes, which suggests that further experiments of these compounds, in particular, for compound 13, are required to evaluate the real potential of the hybridized N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines.

In 2013, Chauhan´s group prepared a series of 19 novel quinolines with a triazine indole-thiol alkyl amine at the 4-position (structure 15 in Figure 11B) to be proved against L. donovani promastigotes and amastigotes (Sharma et al., 2014). The nature of the hybridization of the triazino indole-thiol-ethylene amino focused on three structural features: (i) the length of the linker (sulfur-alkyl-amino) between the quinoline and the triazino indole; (ii) the N-alkyl group incorporated at the indole nitrogen; and (iii) the substitution pattern on the indole’s aromatic ring (C-6 and C-8 position).

From a SAR analysis, the influence of the chain length of the linker, the N-indole alkylation, and indole pattern substitution are clear. In general, the short alkyl chain (two carbons, ethylene, compound 16) provided the most active and selective compounds, finding a monotonic increase of potency and selectivity as a function of the number of carbon atoms as follows: 2C > 3C > 4C > 5C > 6C > 7C > 8C. Interestingly, increasing this carbon chain increases the toxicity of the compounds on J-774A.1 macrophage cells, which compromises the selectivity. Regarding the N-alkyl indole substitution, it was found that N-methyl substitution provided the most active compound, finding a monotonic increase of leishmanicidal response as a function of N-alkyl substitution as follows: N-methyl > N-ethyl > N-propyl > N-butyl > N-pentyl. N-methyl derivative showed an IC₅₀ value of 0.36 µM, and the no N-substituted hybrid displayed an IC₅₀ value of 1.11 µM (compound 17, Figure 11B), whereas a monotonic increase of IC₅₀ was found with an increase of the N-alkyl chain length higher than 1 µM. Other nonlinear N-alkyl chains, like isopropyl, sec-butyl, allyl, and benzyl, were found to have lower activity levels with IC₅₀ values as high as 29.48 µM. Finally, regarding the substitution pattern on the indole’s aromatic ring (C-6 and C-8), except for the introduction of a 6-CF₃ group (IC₅₀ = 6.46 µM), the introduction of any other functional group led to toxic derivatives or derivatives with no leishmanicidal activity (Figure 11B). In summary, Chauhan´s group identified a high selective compound, compound 16, which presented a high level of activity (IC₅₀ = 0.36–7.10 µM) and considerable selectivity indexes (SI from 7 to >1111). Interestingly, the compounds were significantly more selective toward the amastigote form than the promastigote strain.

In 2014, S. Adhikari and co-workers prepared a series of 7-chloro-N-[2-(1H-5-ferrocenyl-1,2,3-triazol-1-yl)ethyl]quinolin-4-amines (compound 18, Figure 12A) (Yousuf et al., 2015), and they were proved against in vitro models of L. major and L. donovani. The designed chemical system presents two important structural characteristics: (i) a heteroaryl moiety with basic characteristics at the end of the amino-ethylene chain and (ii) a ferrocenyl moiety that can be interesting due to the role of iron in Leishmania recognition. The compound displayed IC₅₀ values of 21.86 µM and 15.26 µM against the promastigotes of L. major and L. donovani, respectively, which was in same range as the leishmanicidal derived from reference miltefosine (IC₅₀ = 21 µM) and to other quinoline references such as chloroquine (IC₅₀ = 30.00 µM) and ferroquine (IC₅₀ = 19.62 µM). The compound exhibited an apparently more significant leishmanicidal response against intracellular amastigotes of L. donovani in peritoneal macrophages without cytotoxicity toward murine splenocytes, achieving an inhibition of 83.62% upon treatment of 15 µM (value of IC₅₀ determined from the anti-promastigote response against L. donovani). The latter revealed that compound 18 was more active against the amastigote form than against promastigotes, which implies that specific targets concerning macrophage-amastigote biological systems could be involved. Further studies showed that compounds promoted changes in the mitochondrial depolarization potential with further biological consequences in promastigote parasites. Scanning electron microscopy (SEM) studies revealed changes in the shape of promastigotes under compound 18 treatment, including loss of flagella and the appearance of porosity in cell membranes with respect to the flagellated and slender non-treated promastigote controls. Flow cytometric analysis showed an increase of the sub-G0/G1 phase from 2.98% (at 6 h) to 9.43% (at 24 h) in comparison with 3.49% in control cells at 24 h. Further assays based externalization of phosphatidylserine residues showed that the percentages of early and late apoptotic cells were increased significantly with respect to untreated cells, finding values of 1.60% and 1.94% (early apoptotic) and of 0.58% and 0.24% (late apoptotic) at 24 h and 48 h, respectively, for untreated promastigotes, and a significant increase under treatment to 12.74% and 23.45% (early apoptotic) and to 18.67% and 24.69% (late apoptotic) at 24 h and 48 h, respectively. Further assays showed that (i) compound 18 promoted a depletion of GSH in a time-dependent manner after 3 h with the highest MFI with respect to the untreated cells; (ii) DNA fragmentation in promastigotes; (iii) increase of ROS level in a time-dependent manner after 3 h of treatment with respect to control culture, (iv) a substantial increase of NO production in comparison with an untreated model of infected macrophages with intracellular amastigotes, and (v) an increase of the levels of lipid peroxides in a time-dependent manner after 1 h and, in particular, after 3 h. With this evidence, the authors proposed that compound 18 acts through an oxidative mechanistic pathway, which is promoted by the presence of the ferrocene moiety in compound 18. That chemical function induces peroxidation of lipids in the treated promastigotes, which subsequently promotes a decrease in the protein content and changes in the nature of lipidic membranes. This latter induces a loss of mitochondrial membrane potential, leading to apoptosis in L. donovani promastigotes. In addition, the release of NO in the infected macrophage model suggests that the compound can also upregulate the innate immune response.

Next, in 2015, following the Adhikari research, Yousuf and co-workers prepared a series of 13 derivatives of ferrocenylquinolines to be proved against L. donovani and L. major (Yousuf et al., 2016). Four compounds were identified as promising agents against promastigote strains of L. donovani AG83 (compounds 19–23, Figure 12B). Compound 20, which bears a hydrogen atom as the R substituent (structure 19 in Figure 12B), showed the highest antipromastigote activity, with an IC₅₀ value of 15.26 µM, which was more potent than miltefosine (IC₅₀ = 21 µM). Compound 20 is the same as compound 18 (Figure 12A), which was studied by Adhikari (Yousuf et al., 2015). Lower antipromastigote responses with IC₅₀ values between 22 µM and 28 µM were found for those ferrocenylquinoline derivatives with a heteroaryl/aryl as the R substituent. It revealed that the incorporation of an extra aryl/heteroaryl ring did not favor the leishmanicidal response with respect to the prior compound 18. Further assays showed that the ferrocenylquinoline 20 was also able to inhibit the growth and proliferation of L. donovani LV9 (44.28%) and L. major LV39 (52.74%) at 21.8 µM.

Regarding the amastigote stage of L. donovani AG83, compound 20 was also able to considerably affect the amastigotes in 50% at 0.5 µM, which supported the specificity of this type of quinolinic compound toward the amastigote form over the promastigote form. Further mechanistic experiments showed, as was described for compound 18, that this type of compound could arrest cell cycle progression from the increase of sub-G0/G1 cells to 32.88%, 27.31%, and 25.14%, respectively, compared to 2.07% of the control cells after 48 h of treatment. The parasite death was induced by triggering apoptosis. Furthermore, an increase in NO production was recognized from the infected macrophage model under treatment with compound 20, which opens the door to an immunostimulation role.

In 2015, E.S. Coimbra and co-workers prepared a series of novel ten derivatives of 7-dichloroquinoline functionalized at the 4-position by sulfonamides- (24), hydrazide (25) or hydrazine (26) substitutions (Figure 13A), and the compounds were proved against the amastigote and promastigote forms of L. amazonensis (Antinarelli et al., 2015). From sulfonamide derivatives 24, only those functionalized with pyridine (27) displayed good leishmanicidal activity against the promastigote and amastigote forms of L. amazonensis, giving IC₅₀ values of 10.9 µM and 26.6 µM, respectively. However, its discrete cytotoxicity on macrophages (CC₅₀ > 30 µM) compromises its potential by low SI values close to 1.1. Meanwhile, within the hydrazide compounds 25, only derivative 28 featuring a 3-pyridin heteroaryl exhibited a good antiamastigote response (IC₅₀ = 1.9 µM) with a selectivity index of 15.8. Other derivatives consisting of a phenyl or 4-pyridin as the R group in compound 9 generated a discrete anti-amastigote response (IC₅₀ between 16.5 µM and 20.7 µM). Finally, quinolin-4-hydrazine and compound 29 exhibited the best antileishmanial activity with IC₅₀ of 0.8 µM and 2.4 µM and SI of 37.5 and 12.5, respectively.

A rapid SAR analysis reveals that the incorporation of basic moieties, such as can be seen in structures of groups 24 and 25, can be an essential pharmacophore for generating active and selective leishmanicidal compounds. Furthermore, the inclusion of a lipophilic moiety into a hydrazine compound (group 26) could be essential. Interestingly, as seems to be typical in quinoline derivatives, this type of quinoline showed higher activity against the amastigote form than against the promastigote. Mechanistic experiments showed that the compounds can inhibit mitochondrial depolarization potential either in promastigotes or in infected macrophages. For example, a significant reduction in the potential of the mitochondrial membrane in the infected macrophage model was reported with values of 43.6%, 36.7%, and 53.0% under 7.0 μg/mL, 13.0 μg/mL, and 27 μg/mL doses of compound 29, respectively. The latter was comparable with the depolarization induced by miltefosine (25 μg/mL) of 58%, which is known as a disrupter of membrane potential. The authors found a linear correlation between the anti-amastigote response and the decrease in the ΔΨ _m magnitude.

In the same year, M. Pollastri and co-workers prepared a series of 16 quinolines 29b with a 4-(benzyloxyl)-aniline and another with a dialkylamine-sulfoxylfenil moieties at the 4- and 6-position (Figure 13B) (Devine et al., 2015). The compounds were evaluated against a diverse type of neglected tropical disease parasite strains, including T. brucei, T. cruzi, Plasmodium falciparum, and L. major. The quinolinic compounds were divided into two parts: (i) 4- and 6-substituted quinolines and (ii) 4-, 6-substituted 3-cyanequinoline. A consistent SAR analysis was extracted against the L. major amastigote parasite. The authors focused their study on the pattern of benzyloxy moiety, quinoline substitution at the 3-position, and the nature of the aryl-substitution at the 6-position. First, the incorporation of benzyloxy-aniline moiety generated the most active compound of the 4-aminoquinolines 29b. Regarding the benzyloxy moiety, it was found that the fluorine substitution at the 3-position of the benzyloxy ring provides a more active and selective compound than compounds featuring hydrogen atoms. Meanwhile, at the 6-substitution, the sulfonyl-homopiperazine was identified as the most convenient aryl-substitution for the development of the most active and selective compounds. A direct amine (e.g., morpholine) implied a decrease in leishmanicidal activity. Meanwhile, the incorporation of sulfonyl-morpholine and -piperazine aryl-substitution compromises the selectivity in compound 29b. The inclusion of a cyane moiety at the 3-position of quinoline decreases the activity and selectivity, suggesting that unsubstituted quinolines maintain a significant leishmanicidal response. From the study, two compounds, 30 and 31, were identified as the most promising compounds, giving IC₅₀ values of 0.4 µM and 1.6 µM against promastigotes, respectively, and IC₅₀ values of 0.89 µM and 2.3 µM against the amastigote strain, respectively. It implied SI values of 5.5 and 6.0 for compounds 30 and 31, respectively. No mechanistic exploration was explored for the 29b type of quinolines.

In 2016, E.S. Coimbra prepared a series of 7-chloroquinolin-4-arylhydrazones 32 and evaluated them against promastigote and amastigote forms of L. amazonensis (Antinarelli et al., 2016; Antinarelli et al., 2020) (Figure 14A). Although it is not exactly a 4-aminoquinoline type compound, the existence of the NH-moiety at the 4-position is the key point for our selection. Only two of the ten synthesized compounds displayed an acceptable leishmanicidal response against intracellular amastigotes and low toxicity on murine macrophages (CC₅₀ > 150 µM). In particular, compounds 33 and 34 with a 3-hydroxy-phenyl and a 3-formyl moiety, respectively, displayed IC₅₀ values of 8.1 µM and 15.6 µM, respectively, which implied selectivity indexes higher than 18 and 10, respectively. Compound 33 was identified as a promising candidate with a better SI (higher than 18) than miltefosine (SI 15.4). Interestingly, those compounds displaying a good antiamastigote activity showed a weak response against promastigotes, which confirmed the high specificity of the quinoline scaffold toward the amastigote stage over the promastigote stage.

Mechanistic studies showed that compounds using compound 33 induced mitochondrial protozoan dysfunction with a dose-dependence, which was in good correlation with a reduction of parasite proliferation in intracellular parasites with intracellular parasite death. Further mechanistic studies reflected that active compound 33 promoted an increase in the ROS levels in vitro models of promastigote- and L. amazonensis-infected macrophages. In addition, the authors found changes in the level of key factors such as GSH in promastigote models. Through SEM, morphological changes were seen in the parasite shape with loss of flagella compared with flagellated untreated control promastigotes. Further experiments in the amastigote model showed no significant increase in NO production under different concentrations compared with untreated L. amazonensis-infected macrophages. This fact suggested that the leishmanicidal activity against the intracellular parasite promoted by compound 33 is possibly more associated with ROS production than immunological activation. In vivo studies in the CL model showed that compound 33 led to a significant reduction (48.3%) of cutaneous lesions compared with the control group, finding results comparable to amphotericin reference. Interestingly, the parasitic load was found to be significantly reduced by 93.8% compared to the control group, which was comparable to the parasitic load reduction derived from the AmpB group.

In the same year, E.S. Coimbra presented a series of five 7-chloroquinolines 35–39 featuring an ethylene chain with thiol, amine, or hydroxyl at the beginning or end of the 4-functionalized chain (Coimbra et al., 2016) (Figure 14B), and they were proved against in vitro models of L. amazonensis (intracellular amastigotes and promastigotes). Only the derivatives 35 and 37, which bear a 2-aminoethyl-thionyl or a 2-chloroethyl-thionyl chain, respectively, showed a leishmanicidal response with a discrete IC₅₀ of 52.9 µM and 27.9 µM against promastigotes of L. amazonensis, respectively. Compound 35 exhibited a strong inhibition of the proliferation of L. amazonensis amastigotes, giving an IC₅₀ value of 0.0911 µM and a selectivity index of 1063. This compound was 139-fold more potent than miltefosine (IC₅₀ of 12.7 µM) against amastigotes of the L. amazonensis parasite. The high activity against amastigotes and low toxicity on murine macrophages and human erythrocytes were interesting for further assay. Further experiments using compound 35 demonstrated that the compound could promote a decrease in mitochondrial membrane potential and an increase in the ROS level. No substantial NO production in infected macrophages treated with this compound was detected. Compound 35 showed a decrease in the mitochondrial membrane potential (24.8%) only under a high compound concentration (106.0 µM, two times of IC₅₀ against promastigotes). Further experiments showed that compound 35 promoted ROS production with percentages of 60.8% and 54.2% under 53.0 µM or 106.0 µM, respectively.

In 2017, B. Insuasty and co-workers prepared a series of 37 new derivatives of 7-chloroquinolines functionalized at the 4-position by substituted 4,5-dihydro-1H-pyrazole- or chalcone-anilines (40 and 41) (Ramírez-Prada et al., 2017) (Figure 15A), and they were proved against in vitro models of Leishmania panamensis amastigotes. In general, the quinoline-chalcone derivatives 40 displayed better antileishmanial activity against Leishmania panamensis intracellular amastigotes than those quinolines based on 4,5-dihydro-1H-pyrazoles 41. Most of the studied quinoline-chalcones 40 showed good IC₅₀ values ranging between 0.79 μg/mL and 2.54 μg/mL. The most active compounds had a 4-chloro, 4-bromo, or 4-methyl substitution in the aryl moiety. However, they were highly cytotoxic with low CC₅₀ values of approximately 0.7–2.0 μg/mL on promonocytic human cell U-937 cells. Meanwhile, among the quinoline-based 4,5-dihydro-1H-pyrazoles 41, although their derivatives displayed lower leishmanicidal response than quinoline-chalcones, their derivatives displayed acceptable SI values of about 17.1, 14.9, 16.6, and 72.2 for some derivatives including (R₂ = Ph, R₁ = 4Cl), (R₂ = Ph, R₁ = 3,4,5-(OMe)₃), (R₂ = 3,4-DiClPh, R₁ = 4Cl), and (R₂ = 3,4-DiClPh, R₁ = 4Br) as consequence of their low cytotoxicity. Then, the leishmanicidal activity of the quinoline-based 4,5-dihydro-1H-pyrazoles was dependent on the nature of the R₁ and R₂. The R₁-substitution was essential to generate active compounds, where the phenyl moiety provided more active compounds than those derivatives with formyl or acetyl moieties, which implies the importance of the incorporation of a highly lipophilic moiety like phenyl. Meanwhile, the R₂ substitution allowed modulating the level of biological activity, finding the most active and selective response for the R₁-substitution of 4-bromo-, 4-chloro-, or, eventually, 3,4,5-trimethoxy-. Importantly, none of the compounds presented an IC₅₀ lower than amphotericin B (0.05 μg/mL). From both chemical platforms 40 and 41, compounds 42 and 43 were identified as the most active and selective of the compounds, respectively, although they were sufficiently active for further assays. No mechanistic assays were reported by the authors.

In 2018, E.A.F Coelho’s group prepared compound GF1061 (compound 44) from the coupling between the N-(2-bromoethyl)-7-chloroquinolin-4-amine with an excess of 4-fluoroaniline in the presence of potassium carbonate in DMF under reflux. The compound was proved against in vitro models of L. amazonensis and L. infantum. GF1061 showed a good leishmanicidal response with EC₅₀ values of 4.73 μM and 4.28 μM against promastigotes of L. amazonensis and L. infantum parasites, respectively (Tavares et al., 2019) (Figure 15B). Against axenic amastigotes, GF1061 displayed EC₅₀ values of 4.06 μM and 3.74 μM against L. amazonensis and L. infantum, respectively. AmpB presented IC₅₀ values of 0.13 μM and 0.09 μM against L. amazonensis and L. infantum promastigotes, respectively, and of 0.39 μM and 0.30 μM against their amastigote strains, respectively. Despite the higher biological response of amphotericin to compound 44, the quinoline compound displayed a lower toxicity (CC₅₀ of 183.0 μg/mL) than amphotericin (57.64 μg/mL), which implied SI values of 45.0 and 48.9 against the amastigotes, respectively, which was superior to SI values of 2.2 and 2.7 found for amphotericin. Regarding the study against intracellular amastigotes, a significant reduction in infection was found for infected macrophages treated with GF1061, finding % infection lower than 25% for a GF1061 concentration of approximately 2.5 μM. That higher leishmanicidal response against intracellular than axenic forms of the parasite confirms the high preference of the 4-aminoquinoline scaffold toward clinically relevant amastigotes in infected models. Further assay showed that GF1061 promoted a significant reduction in the mitochondrial membrane potential (Δψ _m ) in the in vitro promastigote model of L. infantum, giving values of 34.3% and 34.5% upon compound concentrations of 2.98 μg/mL and 5.96 μg/mL, respectively. Further assay showed that compound 44 induced an increase in the levels of intracellular ROS in promastigote parasites upon the action of the compound at 6 h or 24 h. Analysis of parasite membrane integrity showed that the treatment with GF1061 induced significant morphological alterations in Leishmania promastigotes. Further evaluations showed that alterations in the parasite cell cycle were found in the G0/G1 phase for the treated parasites, which suggests the ability of the compound to promote DNA fragmentation. The cell integrity alterations were interpreted from the significant reductions in the G1 and G2 phases in treated parasites.

Further assays based on phosphatidylserine exposure in the cell surface showed the absence of an apoptotic process in the GF1061-treated parasites with strong evidence of death via necrosis. No substantial NO production in infected macrophages treated with this compound was detected. The leishmanicidal response of compound 44 could be associated with the depolarization of mitochondrial potential, which promoted ROS production that subsequently induced alteration in the cell cycle by death via necrosis with morphological consequences. Finally, compound 44 showed a significant in vivo efficacy for a VL model, finding an appreciable reduction in parasitemia in the infected tissue, liver, spleen, and dLN, giving a percentage of parasitemia reduction of 66%, 69%, 71%, and 72%, respectively, which was comparable with results found under the amphotericin drug of 62%, 44%, 38%, and 48%, respectively. Compound 44 emerged as a potential candidate as a leishmanicidal agent with an appreciable effect of depolarization on mitochondrial potential as the main mechanism of action.

In 2019, Coelho’s group prepared a new type of 4-aminoquinoline called AM1009, compound 45. That compound was synthesized through a direct reaction between the N-(3-bromopropyl)-7-chloroquinolin-4-amine and an excess of cyclohexanamine in the presence of potassium carbonate under reflux (Sousa et al., 2019) (Figure 16). AM1009 was evaluated in vitro against L. amazonensis and L. infantum promastigotes and their axenic amastigotes. AM1009 showed a good antileishmanial response with EC₅₀ values of 2.41 μM and 0.38 μM against the promastigotes of L. amazonensis and L. infantum, respectively. Against axenic amastigotes, AM1009 displayed EC₅₀ values of 1.03 μM and 0.98 μM against L. amazonensis and L. infantum, respectively. AM 1009 showed lower leishmanicidal activity than amphotericin drug (0.13 μM and 0.09 μM against L. amazonensis and L. infantum promastigotes, respectively, and of 0.34 μM and 0.18 μM, respectively), but interestingly, AM1009 was less toxic on murine macrophages than amphotericin (CC₅₀ value of 148.94 μM vs. 0.85 μM), which also implies better SI values of 144.6 and 392.0 against axenic amastigotes of L. amazonensis and L. infantum, respectively. Amphotericin displayed SI values of 2.5 and 4.7. Importantly, AM1009 showed lower toxicity against red blood cells with an RBC₅₀ value of 1739.69 μM. Against the infected model of macrophages, AM1009 displayed a reduction of infection higher than 50% for concentrations of 0.18 and 0.34 μM against models of L. infantum and L. amazonensis, respectively, which are in same range to IC50 values found for the amphotericin drug against these infected models. Mechanistic assays revealed that AM1009 induced a significant decrease of mitochondrial membrane potential at 2 μM (24.6%) against promastigotes of L. amazonensis, which was comparable to that found for the FCCF reference (35.9%). These results were in good concordance with a higher production of ROS and significant alterations in their cell cycle by the occurrence of cells in the sub-G0/G1 phase and the formation of autophagic vacuoles promoted on L. amazonensis promastigote parasites treated with AM1009. All these results indicate cell apoptosis promoted by AM1009. A further assay based on immunological studies showed high levels of the cytokines IFN-γ, IL-12, and GM-CSF, a significant increase of nitrite ions, and an increase in levels of the parasite-specific IgG2a isotype antibody. These results suggested that AM1009 could be acting as an immunostimulating agent, favoring the development of polarized Th1 response, which increases the levels of essential citoquines and NO. In addition, in the parasite, the compound promoted depolarization of mitochondrial potential, which induces the increase of ROS, and, subsequently, changes in the cell cycle. Therefore, AM1009 could have a double action, an immunostimulant activity and a leishmanicidal action derived from alteration in mitochondria functions. Finally, for a murine model of CL infected with L. amazonensis, AM1009 achieved a significant decrease in the size of the lesion and parasite load in infected mice, with a better efficacy than amphotericin.

In 2018, Bogdan A. Solaja’s group designed and synthesized a series of 30 7-chloroquinolines featuring alkyl-diamino chains at the 4-position with different structural characteristics involving the incorporation of aryl- or rigid alkyl groups at the end of the alkyl-diamino chain (Konstantinović et al., 2018) (Figure 17). Furthermore, other chemical functions at the 3- and 7-positions were incorporated into synthesized compounds. The compounds were divided into seven groups: (i) group I consisting of chloroquine analogs functionalized at 3-position by nitro and amino moieties, (ii) group II consisting of chloroquine analogs with an adamantino moiety at the end of the alkyl-diamine chain, (iii) group III consisting of chloroquine analogs with a benzothiazole moiety at the end of the alkyl-diamine chain, (iv) group IV consisting of chloroquine analogs with a phenyl-3-benzothiazole moiety at the end of the alkyl-diamine chain, (v) group V consisting of tetrahydroquinoline with a diethylamino moiety at the end of the alkyl-diamine chain like chloroquine, (vi) group VI consisting of tetrahydroquinoline with a (4-cyanephenyl)-2-thiophenyl-4-fenil moiety at the end of the alkyl-diamine chain, and (vii) group VII consisting of chloroquine with a (4-cyanophenyl)-2-thiophenyl-4-fenil moiety at the end of the alkyl-diamine chain. A structure–property relationship analysis showed compounds from group II to group VII showed a sub-micromolar response against L. infantum and Leishmania tropica promastigotes (0.3–4.0 µM), whereas the compounds of group I showed a weaker response (4.0–10.0 µM). From the antipromastigote response, no significant differences in biological activity were found between compounds featuring an ethylene-diamine chain and compounds with a propylamine chain. No significant changes in antipromastigote response were found by the suppression of the 7-chloro substitution by hydrogen. Meanwhile, the functionalization at the end of the alkyl-diamine chain leads to appreciable changes in the leishmanicidal response. From this QSAR relationship, eight compounds, 46–53, from group II through group VII were chosen as the most promising compounds for an in vitro evaluation against L. infantum and L. tropica promastigotes (Figure 17), and further in vitro evaluations against intracellular amastigotes of L. infantum parasite were performed. A comparison between selected candidates revealed that the compound with the (4-cyanophenyl)-2-thiophenyl-4-fenil 53 moiety (0.6–0.8 µM) was the most active, followed by those with a benzothiazole (1.0–1.4 µM), whereas a derivative of adamatino showed a significant IC₅₀ of 0.31 µM. Results showed that lipophilicity must be considered, but it seems important that elongated alkyl-diamine chains are not convenient because although active compounds are generated, they promote more side effects on the host cell.

Solaja selected compounds 47 and 50 with selectivity indexes of 3.2 and 8.2, respectively, for further in vivo evaluation for a model of VL. Interestingly, the authors found a significant in vivo response, finding a significant reduction of liver parasitemia by about 99%, using a low compound dose of 5 mg/kg. Despite the results, further toxicity assays are needed to confirm the potential of the compounds as lead candidates. No mechanistic experiments were reported. This report put in evidence the structural relevance of the incorporation of a weak basic moiety like an alkyl-diamine chain with a tertiary amine as well as the incorporation of a lipophilic moiety composed by an aryl-thiophenyl or an adamant moiety.

In 2018, Calixto and co-workers synthesized a series of organic salts from an N ¹ -(7-chloroquinolin-4-yl)-N ² ,N ² -di(prop-2-yn-1-yl)ethane-1,2-diamine 54a-b, 55, and 56 (Calixto et al., 2018) (Figure 18A), and they were evaluated against in vitro models of L. amazonensis, and L. braziliensis. The 4-aminoquinoline 54a previously showed a discrete activity against different Leishmania parasites for in vitro models (Carmo et al., 2011). The new organic salts were based on the N-alkyl protonation of 4-aminoquinoline 54a, the N ¹ -methylation, and the double action, N -alkyl protonation, and N ¹ -methylation, to give the corresponding water-soluble compounds 54b, 55, and 56, respectively. This cationization seeks to improve the leishmanicidal response through an improvement of the physical-chemical properties. The three cationic compounds were evaluated for their leishmanicidal response against L. amazonensis and L. braziliensis promastigotes and amastigotes. The results of the in vitro evaluation against promastigotes demonstrated that only the derivative 54b was effective against both species of Leishmania (IC₅₀ [L. amazonensis] = 43.25 µM and IC₅₀ [L. braziliensis] = 39.19 µM). Furthermore, only compound 54b was active against L. amazonensis-GFP intracellular amastigotes (IC₅₀ = 5.48 µM), and that antiamastigote activity was very similar to that observed against L. amazonensis-Wild type amastigotes (IC₅₀ = 5.62 µM). Importantly, compound 54b presented a low level of toxicity against murine macrophages (IC₅₀ = 226.70 µM), making compound 54b a promising candidate by its higher SI (by about 40 units) against L. amazonensis amastigote strains. Further experiments confirmed the ability of compound 54b to induce oxidative stress via depolarization of mitochondrial membrane potential. Compound 54b induced a reduction of ∆Ψ _m of 28% at a compound concentration of 86 µM. Interestingly, the compound displayed a reduction of mitochondrial potential comparable with that displayed under miltefosine, and no effect on the mitochondrial potential was observed for uninfected macrophages under treatment with compound 54b. On the other hand, compound 54b at 86 µM in culture promoted an increase of ROS production by about 62%, which was similar to miltefosine (68%) (Figure 18B). In addition, TEM revealed that compound 54b promoted some morphological modifications such as rounded bodies and reduction of cell volume. To analyze the reason for death, TEM showed that promastigotes, upon treatment with compound 54b, induced exposure of phosphatidylserine on the parasite surface, reflecting an increase of the cell population in the sub-G0/G1 phase with condensed and marginalized chromatin, suggesting death via apoptosis.

In addition, in 2018, S. Stevanovic’s group identified a substituted 6-methoxy-quinalidine 57 (Figure 18C) from a virtual screening of the L. infantum type 2 NADH dehydrogenase (NDH2) for a group of ubiquinone analogs including a 4-aminoquinoline, phthalazine, quinolone, and other N-heteroarenes (Stevanovic et al., 2018). The quinolinic compound 57, as well as other N-heteroarenes ubiquinone analogs, were evaluated in vitro against L. infantum axenic amastigotes and promastigotes. Compound 57 exhibited an excellent leishmanicidal response against the wild type of L. infantum, giving IC₅₀ values of 0.03 and 0.2 µM against promastigotes and amastigotes, respectively. Later, Rivas’s group reported a good response against L. donovani promastigotes and Leishmania pifanoi amastigotes, giving IC₅₀ values of 4.4 µM and 6.2 µM, respectively. Rivas´s group also reported a moderate cytotoxicity with a CC₅₀ value higher than 50 µM using J774A.1 macrophages, which implies SI indexes higher than 250 and 8.1 for in vitro amastigote models of L. infantum and L. pifanoi, respectively. This report is an interesting finding because it showed that the incorporation of an extra basic alkyl chain is needed to generate a potent and selective compound, although it cannot be discarded if the N-alkyl chain could increase the leishmanicidal effect even more.

Based on the widely known potential of quinoline derivatives as antileishmanial agents, another research group designed a new class of 4-amino-2-styryl quinolines 58 and evaluated them against L. donovani promastigotes and L. pifanoi amastigotes (Staderini et al., 2019) (Figure 19). Furthermore, some other derivatives were also synthesized and evaluated to serve as a control group, allowing a deeper understanding of the structural influences of the 4-amino-2-styryl quinolines. Considering their effects against L. donovani promastigotes, the results demonstrated that, except for 2-styrylquinoline (not bear 4-substitution), all the evaluated molecules with a 4-N-alkyl chain present considerable leishmanicidal properties, giving IC₅₀ values ranging from 0.2 µM to 35.1 µM. Interestingly, most of the evaluated compounds were more potent, making it possible to verify the importance of a 2-styryl group, whose remotion led to a considerable loss of leishmanicidal activity. Four compounds 59–62 were chosen as promising candidates for their good leishmanicidal profile (Figure 19). From the leishmanicidal response, compounds displayed a higher activity against the amastigote strain than against the promastigote strain. Against Leishmania amastigotes, compounds presented low IC₅₀ values from 0.9 µM to 1.6 µM for compounds 59–62. In particular, compound 61 exhibited the highest SI value, giving a magnitude higher than 42. The compound is characterized by an aniline as terminal moiety on the N,N-dialkyldiamine chain, which seems to be more convenient to increase the selectivity than dialkyl amine or methoxy as terminal moieties on the N,N-dialkyldiamine chain.

Beyond the leishmanicidal effect, the authors explored the mechanism of action based on mitochondrial dysfunction. First, the author studied the levels of intracellular ATP upon compound treatment using L. donovani promastigotes from the 3-Luc strain. This parasite expresses a cytoplasmic form of firefly luciferase that is episomally encoded. At 50 mM compound concentrations, most of the studied compounds 58 induced a decrease in luminescence, which supports the decrease in ATP synthesis. To demonstrate that the drop in ATP production is associated with permeabilization, the authors explored the permeabilization by the addition of triton X-100, finding no alteration of the plasma membrane permeability. Alternatively, the authors studied the effect of these compounds on membrane mitochondrial potential, finding a decay of ΔΨ _m compared to negative controls. Accumulation into mitochondria using mitotracker supports the role of the parasite mitochondria as a target for compounds 58, which was demonstrated through confocal microscopy. A TEM study on L. donovani promastigotes showed three key morphological characteristics: (i) a swollen mitochondria, (ii) strong vacuolization of the cytoplasm, and (iii) the appearance of distended acidocalcisomes. This evidence reflects the role of the mitochondria as key targets for promoting apoptosis and also provides evidence for the role of other organelles like acidocalcisome as targets to store divalent Ca²⁺ and heavy cations, Fe²⁺ and Zn²⁺, which could be able to capture quinoline compounds via coordination binding.

In 2019, we reported the activity of a series of dehydroxylated derivatives of isoquine and isotebuquine 63 against in vitro models of L. braziliensis and L. Mexicana (Figure 20) (Romero et al., 2019). These derivatives previously displayed a good antimalarial response with curative properties for an in vivo model of Plasmodium berghei (Romero et al., 2015; Valverde et al., 2017). Regarding Leishmania parasites, interestingly, these derivatives, dehydroxilated from isotebuquine, showed a higher leishmanicidal response than their isoquine analogs either against L. braziliensis promastigotes and L. mexicana parasites (Romero et al., 2019). The latter revealed that the incorporation of the extra phenyl ring on the aniline moiety was essential for promoting a significant leishmanicidal response. Three of the 12 evaluated compounds (64, 65, and 66) showed a promising response for further studies. From cytotoxic assay, derivatives 64, 65, and 66 showed good SI values against L. braziliensis of 11.4, 14.1, and 52.1 and of 17.9, 18.3, and 24.1 against L. mexicana, respectively. Against amastigote strains, compound 64 showed better antiamastigote response (IC₅₀ = 13.88 µM) than compound 65 (IC₅₀ = 22.56 µM) and compound 66 (IC₅₀ = 19.34 µM), which implied SI values of 14.3, 6.1, and 5.2, respectively. The antiamastigote response of compound 65 was barely higher than glucantime (IC₅₀ = 15.12 µM). Interestingly, compound 66 showed the best antiamastigote response against a resistant strain of L. braziliensis, giving an IC₅₀ value of 25.23 µM (SI 7.8), higher than that found by using glucantime (IC₅₀ > 50 µM). From a mechanistic point of view, a discrete increase of NO was found from an intracellular amastigote model with a concentration dependence, which suggested a specific effect against infected macrophages that could be associated with an immunostimulation response. Currently, we are studying the potential of these derivatives against in vitro models of L. infantum, finding excellent responses against infected models in sub-micromolar ranges.

In 2019, N. Basilico, F. Gamarro, and co-workers development a series of five quinoline hybrids 67–71 as depicted in Figure 21A (Manzano et al., 2019). This research is a continuation of a previous report (Konstantinović et al., 2018). All compounds exhibited significant antipromastigote and antiamastigote responses, giving IC₅₀ values lower than 1 µM (Figure 21A), finding similar leishmanicidal responses between promastigote and amastigote strains. In particular, among the five compounds, compound 67 showed the best SI profile with an SI value of 8.2, whereas the remaining compounds displayed SI values between 2 and 4. A small superficial structure–activity analysis reflects that the location of the 2-benzothiazol at the 3-position of the benzylic-amine is preferred over the location at the 4-position in order to decrease the cytotoxic effect and achieve a higher SI. It is important to mention that the leishmanicidal effect is similar among all studied compounds. On the other hand, mechanistic experiments demonstrated that compound 67 promoted (i) an alteration in the energetic metabolism with a significant loss of ATP that is associated with the depolarization of mitochondrial potential (ΔΨ _m ), (ii) a decrease of intracellular ATP levels with an alteration of plasma membrane permeability, and (iii) a significant ROS production, which is the typical mode of action found for 4-aminoquinolines. This type of mechanism initiates a depolarization of mitochondrial membrane potential, which subsequently promotes ROS production that promotes alterations in parasite morphology with apoptotic consequences as the mode of cell death.

In 2020, P. Fernandez synthesized and evaluated the leishmanicidal activity of two 7-chloroquinoline derivatives 72 and 73. Compound 72 displayed IC₅₀ values of 1.65 and 1.07 against intracellular amastigotes of L. major and L. panamensis, respectively, whereas compound 73 displayed IC₅₀ values of 5.29 and 3.29 µM against L. major and L. panamensis, respectively (Herrera et al., 2016; Herrera et al., 2020) (Figure 21B). Compounds showed CC₅₀ values of 14.03 μM and higher than 30 μM, respectively, which implied SI values of 8.5 and 13.1 for compound 72 and 5.8 and 9.1 for compound 73, against L. major and L. panamensis, respectively. Interestingly, neither compound showed a response against promastigotes at 50 µM (IC₅₀ > 50 µM), which supports the high specificity of this type of quinolines toward the amastigote form over the promastigote form. Further assays showed the tentative immunostimulating response of these compounds. In particular, compound 72 inhibited the production of the pro-inflammatory cytokine of IL-10 by macrophages infected with L. panamensis and L. major in a dose-dependent manner. These results suggest that the compound induced a parasite-killing mechanism through regulation of the macrophage activation, as was explained in Section 2.3.

Further studies demonstrated the efficacy of compound 72 on a murine model of L. panamensis (Herrera et al., 2020). The compound promoted an appreciable reduction of the node inflammation, lesion size, and parasitemia index at the lesion region in a dose-dependent manner. In addition, the authors found a significant reduction in the IL-10 production from the lymph node cells of infected mice. Then, it seems that the incorporation of either a basic moiety or a lipophilic moiety is essential for the development of selective and potent leishmanicidal agents based on 4-aminoquinoline.

At the beginning of 2020, L. Ferrins and M. Pollastri followed a target repurposing and parasite-hopping approach and developed a series of quinoline derivatives originating from the reoptimization of lapatinib to NEU-1953 and further optimizations of this (Ferrins et al., 2018; Mehta et al., 2018; Bachovchin et al., 2019). This entire series of quinoline derivatives was then evaluated for its leishmanicidal potential against L. major and L. donovani intracellular amastigotes (Singh et al., 2020). Focusing on the in vitro leishmanicidal effect against intracellular amastigotes of L. major parasite, many of the designed quinoline hybrid 74 compounds displayed a remarkable leishmanicidal activity (Figure 22A). A SAR analysis showed that the nature of the R₁ and R₂ substituents is pivotal for leading an active and selective compound. Talking about the R₂ substitution, the incorporation of dialkyl amine chains decreased the leishmanicidal activity, whereas the inclusion of amino-1,4-pyrazine generated active compounds. More improvement was found when the pyrazine moiety at the 4-position was replaced by composed phenyl rings. In particular, the substituted anilines such as 3′-chloro-4′-methoxyaniline 75 and 4-(trifluoromethoxy)aniline 76 generated the most active compounds (Figure 22A).

Meanwhile, regarding the R₁ substitution, the 4-(1-methyl homopiperazine)-sulfamoylphenyl and 4-(4-(1-methylpiperazine)-3,5-pyrazinyl moieties at the 7-position generate the most active and selective compounds, whereas its location at the 6-position decrease the leishmanicidal activity. Interestingly, the introduction of methyl-groups at different positions of the quinoline core provides different effects. 6-Methylation improves the leishmanicidal effect, whereas an 8-methylation promotes a loss of activity. From the proved compounds, compounds 75 and 76 were chosen as promising candidates for their high antiamastigote response against infected models of L. major and L. donovani macrophages. Compound 75 was more active against L. major (IC₅₀ = 0.22 µM, SI = 7.3) than against L. donovani (IC₅₀ > 10.0 µM). In contrast, compound 76 was more active against L. donovani (IC₅₀ = 0.023 µM, S.I = 1739 using HepG2 cell as reference) than against L. major (IC₅₀ > 1.5 µM). Compound 76, with an SI of 1739, represents a potential candidate for further evaluation of either mechanistic or in vivo efficacy.

In 2020, S. Adhikari-C.Pal and co-workers prepared a series of novel flexible and water-soluble ferrocenyl quinoline N-quaternized compounds 77 (compounds 78–81, Figure 22B) (Mukherjee et al., 2020). From an in vitro evaluation against intracellular amastigotes of L. donovani, compound 78 displayed the best leishmanicidal response, giving an IC₅₀ value of 0.50 μM, whereas compounds 79, 80, and 81 displayed IC₅₀ values of 0.99 µM, 5.05 µM, and 2.44 μM, respectively. Their activities were comparable with amphotericin B (IC₅₀ = 0.26 μM) and higher than sodium antimony gluconate (IC₅₀ = 170 μM), miltefosine (IC₅₀ = 13.60 μM), and paromomycin (IC₅₀ = 8 μM). Compound 77 was evaluated for in vivo efficacy experiments and mechanistic assays. The ferrocenyl quinoline demonstrated curative properties for mice under L. donovani infection with a dose-dependent response. The in vivo therapeutic effect was achieved either upon noninvasive oral or invasive intramuscular administration. Then, several experiments focused on immunostimulation were performed for compound 77. The water-soluble ferrocenyl quinoline 77 stimulated the secretion of Th1 either under oral or intramuscular administration. Furthermore, a significant induction in the expressions of key pro-inflammatory cytokines, IL-6, IL-12, TNF-α, and IL-1β, was observed at the mRNA level in the treated groups, either oral or intramuscular, in comparison to the infected group. By contrast, the mRNA expressions of the anti-inflammatory cytokines like IL-10 and TGF β were reduced for the in vivo model. Additionally, a significant increase in the level of NO in vivo models was found. The expression of pro-inflammatory cytokines, secretion of Th1, and reduction of expression of anti-inflammatory cytokines suggest that this type of compound must be inducing an immunostimulating response in the infected host. Further mechanistic experiments showed that compound 77 reduced the expression of some enzymes, such as γ-glutamylcysteine synthetase, glutathione synthetase, ornithine decarboxylase, and trypanothione reductase. To verify the induction of apoptosis, downregulation in the expression of Sir2 and enzymes NAD + biosynthetic pathway enzymes, nicotinamidase, Na phosphoribosyltransferase (NAPRT), NAMN adenyltransferase (NAMNAT), and ammonia-dependent NAD + synthetase were found under treatment of compound 77 against in vitro or in vivo model when compared with the untreated models. Finally, from the ADME-properties point of view, compound 77 showed a good pharmacokinetic and pharmacodynamics profile. In summary, compound 77 showed an effective leishmanicidal effect against in vitro and in vivo models of LV with curative properties, convenient ADME properties, and an immunostimulating response.

In 2021, Glanzmann and co-workers prepared a novel series of quinoline-triazole hybrids 82–84 (Figure 23A), and they were evaluated against L. amazonensis promastigotes and intracellular amastigotes (Glanzmann et al., 2021). Considering both promastigotes and amastigotes, the results demonstrated that only derivative 84 displayed a promising leishmanicidal response, with IC₅₀ values of 5.7 µM and 1.1 µM against promastigote and amastigote strains, respectively. That compound was the most selective, displaying an SI value of 16.5, which was higher than typical 1 or 3 of the remaining compounds. On the other hand, mechanistic experiments based on compound 84 showed that it induces a significant reduction of the mitochondrial membrane potential, leading to the disruption of its function. Furthermore, a pronounced generation of ROS was noted under treatment with compound 84. Apoptotic evidence was observed through cytometry. In conclusion, the introduction of a triazole ring induces an improvement in leishmanicidal response, leading to a specific mode of action through interference in the bioenergetic system and plasma membrane permeabilization, with subsequent activation of apoptosis-like and necrosis processes, culminating in cell death.

Finally, Tavares and co-workers developed a series of 1,2,3,4-tetrahydroacridines 86 based on a virtual screening performed against the enzyme S-adenosylmethionine decarboxylase and evaluated them against L. infantum promastigotes (Figure 23B) (Silva et al., 2023). Forty-two compounds were assayed. A SAR study was structured based on their results, and it was possible to verify that the length of the alkyl chain had a significant effect on the leishmanicidal activity of the compound, especially in the case of dimers. Most of the 1,2,3,4-tetrahydroacridines presented high levels of toxicity, with a percentage of macrophage death of about 90% at 10 µM. From the SAR analysis, only compound 87 was a promising candidate with an IC₅₀ value of 0.37 µM, although high toxicity derived from an inhibition percentage of 98% in macrophage proliferation at 10 µM. Based on the relevance of a long alkyl chain as a linker between the quinoline core and the high toxicity of the acridine core, this research group decided to replace the tetrahydroacridine scaffold with a 7-chloroquinoline core to prepare compound 88, which consists of two 7-chloroquinolines connected through an N,N-decan-1,10-diamine chain. The new compound showed a good leishmanicidal response with an IC₅₀ value of 0.60 µM and a CC₅₀ value of 11.69 µM, which implies a good SI value near 20. This replacement allowed the retention of the leishmanicidal response with decreased toxicity.

In summary, the following remarks about generating potent and selective compounds from the different 4-aminoquinolines can be extracted from these reports:

i) The inclusion of a chlorine atom at the 7-position has a detrimental influence;

Table 1 summarizes the most highlighted compounds based on in vitro evaluation against intracellular amastigotes, cytotoxicity on macrophages, and a selectivity index higher than 10. From Table 1, compounds 16 (SI > 1111), 45 (SI = 145 vs. L. amazonensis and 392 vs. L. infantum), 54b (SI = 41.3), 57 (SI > 250), 61 (SI = 41.6), and 76 (SI = 1739) are highlighted as the most promising candidate for further assays and as lead structures to inspire new design. These compounds are within the strictest parameters for the drug discovery of leishmanicidal agents (Don and Ioset, 2014). From the structural point of view, the most selective compounds (16, 45, 57, and 76) are better adjusted to the strict parameters for the design of leishmanicidal agents (Don and Ioset, 2014). The inclusion of a lipophilic moiety (aryl or cyclohexyl) at the end of the 4-diamine chain, as well as the incorporation of a composed N-aniline moiety, such as 4′-phenoxy-aniline, into the structure of compounds 57 and 76 at the 4-position of the quinoline core is highly convenient for generating selective compounds as a consequence of the decrease of the cytotoxicity, conserving the leishmanicidal response. In particular, a comparison of compounds 57 and 76, which bear an N-anilino moiety at the 4-position of quinoline core, showed that the incorporation of an extra basic moiety like phenyl-piperazine into compound 76 significantly enhances the selectivity compared with compound 57. A comparison between 4-aminoquinolines featuring an alkyl-amine chain at the 4-position revealed that the inclusion either of a basic moiety or of a lipophilic moiety at the end of the amine chain improves the activity and selectivity, such as can be seen in compounds 16 and 45. These features are also of great relevance for the accumulation in the host lysosome (Trapp et al., 2008) and parasite mitochondria (Duenas-Romero et al., 2007; Coimbra et al., 2010) as well as for promoting a consistent immunostimulant response acting as a TLR agonist/antagonist (Talukdar et al., 2021). Interestingly, when the size of the alkyl-amine chain at the 4-position is increased, the selectivity is compromised as a consequence of an increase of the cytotoxicity on macrophages, as can be seen in compounds 67 (SI = 8.2), 72 (SI = 13.1), 84 (SI = 16.5) and 88 (SI = 19.5). That tendency was appreciated in the quinolinic compound prepared by Bertinaria´s group (Guglielmo et al., 2009) (Figure 10), B.A. Solaja´s group (Konstantinović et al., 2018) (Figure 22), and Manzano et al. (2019) (Figure 21A). On the other hand, the ferrocenyl quinoline also proved to be a convenient scaffold for generating potent and active compounds against in vitro and in vivo models of VL. In addition, it is important to mention that the presence of an extra basic moiety is highly convenient for generating water-soluble compounds by the generation of protonated salts, such as can be seen for compounds 54b and 78, which is a physicochemical property that is highly desired for in vivo models using oral administration.

A few of the compounds mentioned in Table 1 have been proved against in vivo models of VL. In particular, compound 45 was proved against an in vivo model of VL of L. infantum, promoting a significant reduction of parasitemia (66%–72%) larger than that promoted by amphotericin (42%–62%). Other groups of compounds, including compounds 20, 33 (SI > 18), 72 (SI = 13.1), and 78, displayed a good in vivo efficacy with parasitemia reduction. In particular, for compounds 20 and 78, beyond the in vivo efficacy, an immunological activation was proved through the increase of pro-inflammatory cytokines. Compound 78 is an attractive alternative to favor the administration and pharmacokinetics due to its solubility in water.

From the synthetic point of view and based on promising compounds shown in Table 1, compounds 20, 29, 33, 45, 54b, 57, 78, 84, and 88 can be prepared from simple and short synthetic routes involving a simple or three-step simple route, requiring only the extra functionalization of 4-alkyl amine substitution and the final step of nucleophilic aromatic substitution at the 4-position in 4,7-dichloroquinoline substrate. Meanwhile, the synthesis of compounds 16, 61, 67, 72, and 76 require complex synthetic routes involving several steps as a consequence of specific functionalization at the quinoline core as well as the incorporation of complex functionalization at the 4-amine chain. In summary, compounds 45 and 78 are attractive scaffolds due to their significant leishmanicidal activity against in vitro and in vivo models of VL and also due to their synthetic feasibility and physicochemical properties for oral administration. Meanwhile, compounds 16 and 76 emerge as promising candidates for further studies to evaluate their potential as leishmanicidal agents.

In the last decades, compounds based on 4-aminoquinoline have shown great potential for the drug discovery of leishmanicidal agents with a well-defined mechanism of action. The present review showed how the 4-aminoquinolines possess a high specificity toward the amastigote strain over the promastigote, which is highly relevant because the first is the stage in clinical manifestations. Furthermore, a SAR analysis comparison based on diverse examples showed that two factors, basicity and lipophilicity, are key parameters leading to a significant leishmanicidal response and are selective. In particular, a tertiary terminal amine and long hydrocarbon chains are required. From the mechanistic point of view, it was found that 4-aminoquinoline targets two key organelles, the lysosome macrophage and parasite mitochondria as well as playing a role in immunostimulation. The incorporation of lipophilic chains is essential when targeting macrophage lysosomes, and fundamental reports indicate that Log P values between 4 and 6 are required. Once within the lysosome, the 4-aminoquinoline enters the parasite, and under the protonated form (under an acidic lysosome pH), the compounds target the mitochondria, where they promote depolarization of mitochondrial potential, which is key to conserving energy production. This latter favors ROS production, decreases ATP production, and promotes parasite apoptosis. Additionally, 4-aminoquinolines could act as TLR agonists or antagonists, which could favor macrophage activation and activate the innate immune macrophage system, which emerges as an extra defense mechanism to attack parasites within the macrophage. Interestingly, a more selective TLR response is found for 4-aminoquinolines with terminal tertiary amine and lipophilic groups.

The present review provides a considerable update on development, taking into account two key aspects: (i) SAR analysis and (ii) identification of key targets and their modulation based on SAR analysis. The information seeks to give the scientific community a more in-depth understanding of the most suitable functionalizations to perform in this particular family of compounds for the construction of potent and selective leishmanicidal agents and how it is possible to modulate the mentioned targets. Our report is a starting point to inspire future investigations directed to the design of leishmanicidal agents based on 4-aminoquinolines.